Universitaetsklinikum Freiburg

Albert-ludwigs-universitat Freiburg

Universitätsklinikum Freiburg

Albert-Ludwigs-Universität Freiurg

Universitaetsklinixum Freiburg

Rheinische Friedrich-wilhelms-universitat Bonn

Eric Metzger

Roland Schuele

Roland Schüle

Bernhard Breit

Manfred Jung

Sheng Wang

Tabea Pappert

Thomas Günther

Nicolas Barthes

Daad Sarraf

Melanie Wissmann

Delphine Duteil

Reinhard Prof Buettner

Roland Prof Schüle

Jutta Kirfel

Roland Schule

Reinhard Büttner

The present invention is inter alia concerned with an inhibitor selected from the group consisting of a selective KMT9-inhibitor, a selective METTL21A-inhibitor and a selective METTL21B-inhibitor for use in the treatment of cancer. KMT9, METTL21A and METTL21B are characterized herein for the first time as histone methyl transferases, and inhibitors of the same can be used for treating cancer.

Inhibition of histone methyl transferases to treat cancer

Disclosed in the present application are: (i) a compound inhibiting the interaction between LSD1me2 and CHD1 for use in therapy, (ii) a compound inhibiting the interaction between LSD1me2 and CHD1 for use in treating cancer, in particular prostate cancer, and (iii) a method of screening for such a compound.

Interaction of methylated LSD1 and CHD1, a compound inhibiting this interaction for use in therapy, and a screening method for such a compound

The present invention relates to the use of a genetically modified non-human animal as an animal model for obesity or obesity-related disorders, wherein the amount of Lysine-specific Demethylase 1 (LSD1) in at least one tissue or at least one cell type of said animal is reduced.

Animal model for type 2 diabetes and obesity

Disclosed is the use of at least one amine oxidase inhibitor for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal and to pharmaceutical compositions for controlling the androgen receptor-dependent gene expression, comprising an effective dose of at least one amine oxidase inhibitor suitable for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal.

Androgen receptor-dependent gene expression control

The invention relates to the use of at least one amine oxidase inhibitor for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal and to pharmaceutical compositions for controlling the androgen receptor-dependent gene expression, comprising an effective dose of at least one amine oxidase inhibitor suitable for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal. The invention also relates to assay systems allowing to test LSD1 inhibitors for their ability to inhibit LSD1 function.

The invention relates to a multiple-specificity demethylase complex comprising a Jumonji C (JMJC) domain-containing enzyme, a process of its preparation and its use.

Tri-demethylation-capable protein complex, method of its preparation and its use

The present invention relates to a process for controlling at least one androgen receptor- (AR-) regulated mechanism in mammalian cells under histone-phosphorylating conditions, said process comprising allowing at least one inhibitor with specificity for at least one protein kinase C-related kinase (PRK) to act on said at least one PRK1 thereby modulating, preferably down-regulating, the activity of said at least one PRK and optionally blocking said at least one androgen receptor-regulated mechanism in said mammalian cells.

Phosphorylation of histone H3 at threonine 11&#x2014;a novel epigenetic mark for transcriptional regulation

The present invention relates to an assay system for specific inhibitors of protein kinase C-related kinases (PRKs) relating to one or more of the reactions wherein said protein kinase C-related kinases are involved under physiological conditions. The invention also relates to a process for identifying specific inhibitors for protein kinase C-related kinases.

Growing community of inventors

Neuf-Brisach, France

Eric Metzger